Biovail Corporation International BVF
-
Biovail and Valeant Merger Takes Place
We have halted our coverage of the old Biovail BVF and the former Valeant VRX companies, now that the companies have merged. The new combined company will take over the Valeant name going forward, and we will publish a new analysis of the merged company shortly.
-
New Morningstar Analyst Report - Biovail Corporation International
… Stewardship Grade; we will determine our grade going forward by how well the integration progresses. Biovail Corporation International is a Canada-based pharmaceutical company that in-licenses and develops specialty drugs in the central …
-
Cost Cuts Ahead for Valeant and Biovail, Valeant's Fair Value Estimate Under Review
We're placing Valeant Pharmaceuticals VRX under review as we update our fair value estimate for merger partner Biovail BVF , whose fair value Valeant's valuation will be tied to going forward. Both stocks jumped on Tuesday on news that the combined …
-
Our Outlook for Health-Care Stocks
… billion. Charles River CRL made inroads into China with a pending $1.6 billion acquisition of WuXi WX. Finally, Biovail BVF and Valeant Pharmaceuticals VRX have announced their intent to merge, creating a strong diversified pharmaceutical firm. Robust …
-
New Morningstar Analyst Report - Flamel Technologies
… s early stage pipeline.Flamel may be left empty-handed if competitors such as Alkermes ALKS, Nektar NKTR, and Biovail BVF develop technology superior to the company's Micropump and Medusa systems.Micropump is the only one of the firm's technologies …
-
Valeant, Biovail to Merge
Valeant Pharmaceuticals VRX and Biovail BVF announced Monday that they have agreed to merge by the end of 2010. The new firm will be named Valeant Pharmaceuticals International …
-
Top Managers to Debate Foreign Hot Spots
… well. Lynn has found a few biomedical and drug stocks that meet his high-growth standards, such as Celgene CELG and Biovail BVF , but he has had trouble finding other names in the sector, and his fund had less than half the foreign large growth norm of …
-
Biovail's Gross Margin Disappoints
We may slightly reduce our fair value estimate for Biovail BVF following a disappointing gross margin in the third quarter. We had expected a significant boost, as a percentage of sales …
-
Labopharm needs trazodone approval to become a sustainable enterprise.
… approved. Its U.S. version of once-daily tramadol faces stiff competition from Ultram ER, a similar drug from Biovail BVF . Biovail has the popular Ultram brand name for tramadol, formidable marketing partner Johnson & Johnson JNJ, and a substantial …
-
Biovail's New Overhang
We're maintaining our fair value estimate for Biovail BVF following predictable second-quarter sales for Biovail's core drugs. Cash flows earned in the first half were countered by …